Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/13/2845281/0/en/Entrada-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/07/2825062/0/en/Entrada-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/01/03/2803161/0/en/Entrada-Therapeutics-Promotes-Nathan-J-Dowden-to-President.html
https://www.fiercebiotech.com/biotech/fda-rebuffs-entradas-attempt-get-year-long-hold-dmd-drug-lifted
https://www.globenewswire.com//news-release/2023/11/22/2784690/0/en/Entrada-Therapeutics-Announces-Updates-on-ENTR-601-44-in-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2023/11/07/2774935/0/en/Entrada-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/10/12/2759085/0/en/Entrada-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2023/09/21/2747134/0/en/Entrada-Therapeutics-Announces-First-Participant-Dosed-in-its-Phase-1-Clinical-Trial-of-ENTR-601-44-for-the-Potential-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2023/09/07/2739173/0/en/Entrada-Therapeutics-Awards-Funding-to-Non-Profit-Organizations-Advancing-Diversity-Equity-Inclusion-and-Accessibility-within-the-Duchenne-Muscular-Dystrophy-Community.html
https://www.globenewswire.com//news-release/2023/08/29/2733242/0/en/Entrada-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html